1. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients 
Timo F.W. Soeterik, Harm H.E van Melick, Lea M. Dijksman, Douwe H. Biesma, J. Alfred Witjes, Jean-Paul A. van Basten 
European Urology Oncology 
Volume 1, Issue 3, Pages (August 2018)
DOI: /j.euo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Percentage of patients not meeting the individual and overall PRIAS selection criteria (n=1000). PSA=prostate-specific antigen; PSAD=PSA density; PRIAS=Prostate Cancer Research International Active Surveillance.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

3. Fig. 2
Kaplan-Meier curves of time to tumour progression during active surveillance (AS). Comparison of (A) PRIAS-eligible versus PRIAS-ineligible patients and (B) prostate-specific antigen density (PSAD) <0.2 versus ≥2 ng/ml/ml.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions